$GRTS News

Last published 2y ago

2y agoGRTSGritstone bio Takes Action to Preserve Value and Strengthen Capital StructureBusiness WireVoluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology
2y agoGRTSGritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal CancerGlobeNewswire--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk
2y agoGRTSGritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature
2y agoGRTSThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 6, 2024 in Gritstone Lawsuit – GRTSGlobeNewswireNEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ:GRTS). Shareholders who purchased shares of GRTS during the class period listed
2y agoGRTSDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GritstonePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gritstone bio, Inc. ("Gritstone" or the...
2y agoGRTSGritstone bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 6, 2024 to Discuss Your Rights - GRTSPR NewswireThe Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS...
2y agoGRTSGritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)GlobeNewswire-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc.
2y agoGRTSGritstone bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – GRTSGlobeNewswireNEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ:GRTS). Shareholders who purchased shares of GRTS during the class period listed
2y agoGRTSInvestors in Gritstone bio, Inc. Should Contact The Gross Law Firm Before August 6, 2024 to Discuss Your Rights – GRTSGlobeNewswireNEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ:GRTS). Shareholders who purchased shares of GRTS during the class period listed
2y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
2y agoGRTSGritstone bio, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 6, 2024 to Discuss Your Rights – GRTSGlobeNewswireNEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ:GRTS). Shareholders who purchased shares of GRTS during the class period listed
2y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
2y agoGRTSGritstone bio to Participate in Upcoming Investor and Scientific ConferencesGlobeNewswireEMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will
2y agoGRTSGritstone bio Inc. (GRTS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoGRTSGritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable
2y agoGRTSGritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024GlobeNewswire-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's
2y agoGRTSGritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024GlobeNewswire-- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants
2y agoGRTSGritstone bio Announces Appointment of Stephen Webster to its Board of DirectorsGlobeNewswireEMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of
2y agoGRTSNature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of "Off-the-Shelf" Neoantigen Vaccine Platform (SLATE)GlobeNewswire-- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including
2y agoGRTSGritstone bio to Participate in Upcoming Investor and Scientific ConferencesGlobeNewswireEMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will
2y agoGRTSGritstone bio Presents Improvements to EDGE™ Platform at AACR 2024GlobeNewswire-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of
2y agoGRTSGritstone bio Announces Pricing of $32.5 Million Underwritten Public OfferingGlobeNewswireEMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an
2y agoGRTSGritstone bio Announces Proposed Public OfferingGlobeNewswireEMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it has
2y agoGRTSGritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)GlobeNewswire-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or
2y agoGRTSGritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewswire-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone's personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q
2y agoGRTSGritstone bio Announces Workforce ReductionGlobeNewswireEMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced an approximately 40%
2y agoGRTSGritstone bio to Participate in Upcoming Investor and Scientific ConferencesGlobeNewswireEMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will
2y agoGRTSGritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical TrialGlobeNewswireEMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it is now
2y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
2y agoGRTSGritstone bio to Participate in Upcoming Investor ConferenceGlobeNewswireEMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will
2y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
2y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewswire-- BARDA contract and IDWeek presentations position Gritstone's self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b head-to-head study evaluating
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGenevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio's BARDA AwardGlobeNewswireVANCOUVER, British Columbia and BASEL, Switzerland, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle
3y agoGRTSPresentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio's Next Generation COVID-19 VaccineGlobeNewswire-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed in all Phase 1
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023GlobeNewswireEMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced results from all
3y agoGRTSGritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 MillionGlobeNewswire-- 10,000 participant randomized Phase 2b study will evaluate Gritstone's self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 -- --
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGritstone bio to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGritstone bio and Genevant Sciences Announce Option and License AgreementGlobeNewswireAgreement provides nonexclusive access to Genevant's leading LNP technology for use with Gritstone bio's self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year, multi-pathogen,
3y agoGRTSGritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewswire-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); preliminary efficacy data
3y agoGRTSGritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) ProjectGlobeNewswireEMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the company
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the
3y agoGRTSGritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature CommunicationsGlobeNewswire-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults (administration post-primary
3y agoGRTSGritstone bio to Participate in Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will
3y agoGRTSGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireEMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the